Paper Details

  1. Home
  2. Paper Details

Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.

Author: , AurpibulLinda, BestBrookie M, CampbellHavilland, CassimHassena, CooperEllen, FlynnPatricia, GrayKathryn P, KrotjeChelsea, McCarthyKatie, McFarlandElizabeth, MelvinAnn J, MoyeJack, OunchanumPradthana, RungmaitreeSupattra, ScheckterRachel, TepplerHedy, TobinNicole H, TownleyEllen, WanHong, YedlaMounika, YeeKa Lai

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the pharmacokinetics (PK) and safety of doravirine and a fixed-dose combination of doravirine, lamivudine, and tenofovir disoproxil fumarate in adolescents with HIV-1. The study found that both doravirine and the fixed-dose combination achieved target PK levels in adolescents and were well-tolerated. The fixed-dose combination maintained excellent virologic efficacy through 24 weeks, suggesting that it may be a favorable option for adolescents with HIV-1.
Paper Details　
Original Abstract of the Article :
BACKGROUND: We studied the pharmacokinetics (PK) and safety of 100-mg doravirine and doravirine/lamivudine/tenofovir disoproxil fumarate fixed-dose combination (100/300/300 mg DOR FDC) treatment in adolescents with HIV-1. METHODS: Adolescents ages 12 to younger than 18 years were enrolled in 2 sequ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/36215957

データ提供：米国国立医学図書館（NLM）

Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate: A Promising Treatment for HIV-1 in Adolescents

This study examines the pharmacokinetics (PK), tolerability, and safety of doravirine and a fixed-dose combination of doravirine, lamivudine, and tenofovir disoproxil fumarate (DOR FDC) in adolescents with HIV-1. The authors highlight the need for safe and effective treatment options specifically tailored for adolescents living with HIV-1.

Effective and Well-Tolerated: Doravirine Offers Hope for Adolescents

The study demonstrates that doravirine and DOR FDC achieve target PK levels in adolescents with HIV-1, with plasma concentrations comparable to those observed in adults. Both treatments were well-tolerated, with no significant adverse events reported. Furthermore, DOR FDC maintained excellent virologic efficacy, with a high proportion of participants achieving or maintaining HIV-1 RNA levels below 40 copies/mL.

A New Frontier in HIV Treatment: Expanding Options for Adolescents

This study provides valuable evidence for the safety and efficacy of doravirine and DOR FDC in adolescents living with HIV-1. The findings suggest that these treatments offer a promising new option for this population, potentially improving their long-term health outcomes and quality of life. Further research is needed to assess the long-term effects of these treatments in adolescents and to explore their potential for use in other pediatric populations.

Dr. Camel's Conclusion

HIV, like a desert mirage, can seem daunting and overwhelming. This study offers a beacon of hope, demonstrating the effectiveness and safety of doravirine and DOR FDC for adolescents. These findings could pave the way for improved treatment options and a brighter future for adolescents living with HIV-1.

Date :
  1. Date Completed 2023-01-12
  2. Date Revised 2023-09-26
Further Info :

Pubmed ID

36215957

DOI: Digital Object Identifier

NIHMS1840983

Related Literature

Article Analysis
・Effects of doravirine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.